Schizophrenia Market Research
Schizophrenia is a severe, lifelong brain disorder. People who have it may hear voices, see things that aren’t there or believe that others are reading or controlling their minds.
Research indicates that the global schizophrenia market was worth $6.7bn in 2009. The global Schizophrenia therapeutics market is forecast to decline with a CAGR of (3.7%) to reach $5.1bn by 2017. This decline in the market is primarily attributed to the release of generics of some of the leading products during the period 2011-2014. The therapeutic market for schizophrenia is expected to decline form 2011 till mid 2014 due to the patent expiry of major marketed drugs such as Zyprexa, Abilify, Seroquel and Geodon. However in the late 2014, the situation is set to improve. There is a huge unmet need in the current market in terms of safety and efficacy. Furthermore, a low treatment seeking rate and low patient compliance rate are likely to act as a barrier to market growth.
The Schizophrenia drug therapy market research report provides insight into the pipeline status of schizophrenia therapeutics by company and by stage, as well as a summary of the latest news and developments in this area. In addition to new developments and disease specific pipeline projects, the listed reports also contain extensive information in tabular format on a company’s full product pipeline, and products by phase of development with regard to the therapy area. The study also helps in keeping track of the industry-specific competitors and partners by better understanding their product pipeline.
The study basically aims at providing a comprehensive overview of the on-goings of the schizophrenia drugs & therapy market.